Recent News

• 06.03.2025 - Karyopharm to Present at the Jefferies Global Healthcare Conference
• 06.02.2025 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.19.2025 - Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
• 05.14.2025 - Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting
• 05.12.2025 - Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification
• 05.08.2025 - Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025
• 05.01.2025 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 8-K Current report
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - 8-K Current report